.Pharmacolibrary.Drugs.ATC.J.J05AR07 .Pharmacolibrary.Drugs.ATC.J.J05AR07| name: | StavudineLamivudineAndNevirapine | |
| ATC code: | J05AR07 | route: | oral |
| compartments: | 1 | |
| dosage: | 300 | mg |
| volume of distribution: | 1.0 | L |
| clearance: | 0.04 | L/h/kg |
| other parameters in model implementation | ||
Stavudine, lamivudine, and nevirapine is a fixed-dose combination antiretroviral medication used in the treatment of HIV-1 infection. Each component targets HIV replication by different mechanisms: stavudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs), while nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). This combination remains in use in resource-limited settings but is not a preferred regimen in current HIV treatment guidelines due to concerns about toxicity and resistance.
Pharmacokinetic parameters estimated based on published ranges for healthy adult HIV-infected patients receiving the fixed-dose combination orally.
Saleri, N, et al., & Matteelli, A (2012). Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. The Journal of antimicrobial chemotherapy 67(2) 469–472. DOI:10.1093/jac/dkr445 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22028201